Greg Anderson, MD
Clinical Neurophysiology · Lexington, KYNPI 1154368801
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,532 of the $8,055 with a category attached, or 68.7%. It is spread thinly across 40 manufacturers, the largest accounting for just 17.4%. Reporting peaked in 2019 at $4,668 and has fallen 97.1% since, to $137 in 2024.
Across 329 payments — averaging $24.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$1K
- AbbVie$1K
- Banner Life Sciences, LLC$900
- Biogen$721
- Teva Pharmaceuticals USA, Inc.$528
- Novartis$457
- plus $3K from 34 others
Across 7 payments — averaging $61,186 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$413K
- Bristol Myers Squibb$12K
- Boehringer Ingelheim$2K
- Eli Lilly$700
What the payments were for
- Consulting fees$4506%
- Speaking & faculty fees$91711%
- Travel & lodging$1,10114%
- Food & beverage$5,53269%
- Education$561%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 5 | $1,404 |
| AbbVie(2 entities) | 72 | $1,123 |
| Banner Life Sciences, LLC | 1 | $900 |
| Biogen | 19 | $721 |
| Teva Pharmaceuticals USA, Inc. | 54 | $528 |
| Novartis | 22 | $457 |
| UCB, Inc. | 15 | $347 |
| Sanofi | 9 | $308 |
| Amgen | 9 | $186 |
| Biohaven Pharmaceuticals, Inc. | 12 | $180 |
| Pfizer | 25 | $179 |
| Sunovion Pharmaceuticals Inc. | 14 | $178 |
| Stryker | 1 | $169 |
| AstraZeneca | 5 | $167 |
| Mallinckrodt Enterprises LLC | 7 | $115 |
| Johnson & Johnson | 1 | $91 |
| Genentech USA, Inc. | 7 | $81 |
| EMD Serono, Inc. | 3 | $81 |
| Arbor Pharmaceuticals, Inc. | 5 | $78 |
| Avanir Pharmaceuticals, Inc. | 4 | $70 |
| Eisai Inc. | 4 | $69 |
| MDD US Operations, LLC | 2 | $64 |
| Merz North America, Inc. | 3 | $62 |
| Acadia Pharmaceuticals Inc | 4 | $59 |
| Akcea Therapeutics, Inc. | 2 | $52 |
| Lilly USA, LLC | 4 | $50 |
| CSL Behring | 3 | $50 |
| Lundbeck LLC | 3 | $46 |
| Promius Pharma LLC | 3 | $39 |
| Merz Pharmaceuticals, LLC | 1 | $32 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Boston Scientific | 1 | $19 |
| Acorda Therapeutics, Inc | 1 | $17 |
| Vertical Pharmaceuticals, LLC | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Upsher-smith Laboratories LLC | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $13 |
| Zyla Life Sciences, Inc. | 1 | $13 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few clinical neurophysiology providers in Kentuckyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CopaxoneGlatiramer Acetate | 23 | $128,399 |
| AptiomEslicarbazepine Acetate | 18 | $30,100 |
| Glatiramer Acetate | 11 | $23,124 |
| DilantinPhenytoin Sodium Extended | 19 | $4,927 |
| Carbamazepine ErCarbamazepine | 11 | $3,265 |
| Levetiracetam | 44 | $1,718 |
| Memantine Hcl | 79 | $1,705 |
| Gabapentin | 91 | $1,507 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 40 | $1,295 |
| Donepezil Hcl | 93 | $1,282 |
| Pregabalin | 19 | $1,132 |
| Oxcarbazepine | 15 | $800 |
| Phenobarbital | 13 | $694 |
| Topiramate | 42 | $464 |
| Lamotrigine | 23 | $457 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Copaxone | $528 | $128,39923 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $178 | $30,10018 claims |
| PfizerDilantin | $179 | $4,92719 claims |
| Upsher-smith Laboratories LLCTopiramate | $16 | $46442 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Kentuckyon file to place this against a meaningful peer group, so we don't.
Other clinical neurophysiology in Lexington
- Warren ChumleyLexington$288K
- Ima EbongLexington$12K
- Ashar FarooqiLexington$3K
- Jordan ClayLexington$2K
- Priyanka YadavLexington$588
- Gaston da CostaLexington$262
- Christopher CroswellLexington$148
- Cecilio HernandezLexington$53
- Disha ShahLouisville$122K
- Ty BrownCrestview Hills$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.